Clinical research results for Kelun-Biotech’s TROP2 ADC sacituzumab tirumotecan (sac-TMT) published in Nature Medicine, ...
CHENGDU, China, April 12, 2025 /PRNewswire/ — Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the “Company”) today announced that results from a Phase 3 registrational clinical study evaluating the novel TROP2 antibody drug conjugate (ADC) …